ArticleESMO real world data and digital oncology2026
Real-world characteristics and invasive disease-free survival of resected patients with HR-positive/HER2-negative early breast cancer: evidence from German population-based cancer registries.
Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hormone receptor-positive (HR-positive) and human epidermal growth factor receptor 2-negative (HER2-negative) tumors are the most prevalent subtypes of early breast cancer (eBC). Despite the generally favorable prognosis, a relevant proportion experiences invasive disease events following surgery. We aimed to describe characteristics, treatment modalities, and survival outcomes of surgically treated patients with HR-positive/HER2-negative eBC in Germany. Materials and methods: This study used data from eight population-based clinical cancer registries in Germany. Patients diagnosed between 2017 and 2021 with HR-positive/HER2-negative eBC who underwent surgery within 4 months of diagnosis were included. Patient and tumor characteristics and treatment received before recurrence were described. Kaplan-Meier statistics and multivariable Cox regression were used to assess invasive disease-free survival (iDFS). Results: A total of 43 214 patients with a median follow-up time of 47 months were included. Among these, 5635 experienced an iDFS event, of which 38.0% were recurrences as the first observed event. Recurrence more often occurred among men, premenopausal women, and patients with larger tumors, greater nodal involvement, and higher tumor grade. The 5-year iDFS was 82.9% (95% confidence interval 82.4-83.3). In multivariable analysis, higher age, tumor size, nodal involvement, histologic grade, and mastectomy compared with breast-conserving surgery were associated with a lower iDFS. Conclusions: These real-world data emphasize that 83% of patients with HR-positive/HER2-negative eBC do not experience recurrence, second primary malignancy, and death within 5 years. The prognostic relevance of established tumor-related factors for iDFS was confirmed in a large unselected patient population in the German routine care setting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.